This clinical trial is focused on studying the effects of a treatment for Systemic Lupus Erythematosus, commonly known as lupus. Lupus is an autoimmune disease where the body’s immune system mistakenly attacks healthy tissues. The treatment being tested is a combination of two medications, Abacavir and Lamivudine, which are typically used to treat viral infections. In this study, they are being used to see if they can help manage lupus by affecting certain immune system signals known as the interferon signature.

The purpose of the study is to evaluate how well the Abacavir/Lamivudine combination works when added to the standard care for lupus over a period of six months. Participants will be randomly assigned to receive either the medication combination or a placebo, in addition to their usual treatment. The study will monitor changes in the interferon signature, which is a pattern of gene activity linked to lupus, to see if the treatment can reduce it. The study will also look at other factors, such as the maintenance of low disease activity, the number of lupus relapses, and the use of other medications like corticosteroids.

Participants in the study will take the medication orally in the form of film-coated tablets. The trial will last for a total of six months, during which time the participants’ health and response to the treatment will be closely monitored. The study aims to provide new insights into the potential benefits of using Abacavir and Lamivudine for treating lupus, which could lead to improved management of the disease in the future.